#264 Alpha Score 65.4

Alex Karnal

Partner, Andreessen Horowitz
· tracked since Apr 2026
264
BUZZBERG Alpha Score combines three things: realized average return, confidence in the sample size, idea volume, and speaker reputation. Speakers with only a few calls are pulled closer to the platform average; speakers with many evaluated ideas keep more of their own return. Reputation only boosts: 5.0 or lower is neutral, while scores above 5 add weight. Scores are normalized to 0-100; 100 is best. Read the FAQ
Alpha Score 65.4
Calls 6 1 Posts tracked · 0.0/day
Calls
7d 0
30d 0
90d 6
Best Calls
GH long +44.6%
LLY long +21.9%
NVO long +8.4%
Worst Calls
XBI long -2.5%
Most Mentioned
NVO ×1
LLY ×1
XBI ×1
Recent Calls
GH long 1 month ago
BIIB long 1 month ago
XBI long 1 month ago
Win Rate 80% Long 6 Short 0
Win Rate
7d 20%
30d 80%
90d —
Average Return +15.6% Long Return +15.6% Short Return -
Average Return
7d -3.6%
30d +10.1%
90d —
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
Opened
Entry
P&L
Thesis
Theme
Source
BIIB Biogen Inc. Biogen Inc.
Long
Apr 21
$185.95
+5.6%
Alzheimer's drugs from Biogen and Lilly are promising.
Anti-amyloid medicines from Biogen and Eli Lilly can break up plaques in the brain and, if given early, could dramatically slow cognitive decline. Data expected later in 2025 may show that early intervention could reduce decline by 40-50% or more.
Healthcare
YOUTUBE
EXAS Exact Sciences Exact Sciences
Long
Apr 21
$2.21
-
Cancer screening companies are growing rapidly.
Companies like Exact Sciences and Guardant Health are advancing colorectal cancer screening with stool-based and blood tests, respectively, making screening more convenient and increasing adoption. Blood tests are inflecting and multi-cancer early detection tests are emerging, which could lead to earlier cancer detection and better outcomes.
Healthcare
YOUTUBE
GH Guardant... Guardant Health, Inc.
Long
Apr 21
$91.99
+44.6%
Cancer screening companies are growing rapidly.
Companies like Exact Sciences and Guardant Health are advancing colorectal cancer screening with stool-based and blood tests, respectively, making screening more convenient and increasing adoption. Blood tests are inflecting and multi-cancer early detection tests are emerging, which could lead to earlier cancer detection and better outcomes.
Healthcare
YOUTUBE
LLY Eli Lill... Eli Lilly and Company
Long
Apr 21
$923.00
+21.9%
GLP-1 drugs are a massive revenue opportunity.
GLP-1 medicines are showing unprecedented adoption and have the potential to be a hundred billion dollar annual revenue class, representing the first commercial proof of a shift to proactive health. They address multiple layers of the health stack, including cardiometabolic health, weight loss, and cardiovascular risk reduction, with oral formulations and lower prices driving further adoption.
Healthcare
YOUTUBE
NVO Novo Nordisk A/S Novo Nordisk A/S
Long
Apr 21
$40.35
+8.4%
GLP-1 drugs are a massive revenue opportunity.
GLP-1 medicines are showing unprecedented adoption and have the potential to be a hundred billion dollar annual revenue class, representing the first commercial proof of a shift to proactive health. They address multiple layers of the health stack, including cardiometabolic health, weight loss, and cardiovascular risk reduction, with oral formulations and lower prices driving further adoption.
Healthcare
YOUTUBE
XBI SPDR S&P... SPDR S&P Biotech ETF
Long
Apr 21
$136.39
-2.5%
PCSK9 inhibitors are a free lunch for heart health.
PCSK9 inhibitors are a nearly free lunch for cardiovascular protection, lowering LDL cholesterol by 50% and reducing heart attack and stroke risk by over 20%. They have the potential to be bigger than GLP-1s in terms of patients and revenue because of their favorable risk-reward profile and the silent nature of high cholesterol.
Healthcare
YOUTUBE
Showing 6 of 6 picks ยท sorted by mentions